Description
A globotriaosylceramide lacking the fatty acyl group; binds to Stx1 in the presence of cholesterol and phosphatidylcholine, but does not bind Stx2; reduces viability and PMA-induced aggregation of human neutrophils (50 and 1 μM, respectively); accumulates in various organs in a mouse model of Fabry disease; accumulates in urine, kidneys, and plasma of patients with Fabry disease; decreases in response to administration of 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease; has been used as a biomarker for efficacy of ERT and other therapies in the treatment of Fabry disease,
Formal name: (2S,3R,4E)-2-amino-3-hydroxy-4-octadecen-1-yl O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside
Synonyms: Globotriaosylsphingosine (d18:1)|Lyso-Ceramide Trihexoside|Lyso-Gb3
Molecular weight: 785.9
CAS: 126550-86-5
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Bacterial Diseases|Shigellosis||Research Area|Lipid Biochemistry|Sphingolipids